CPRX Catalyst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPRX

Price (delayed)

$17.59

Market cap

$2.08B

P/E Ratio

29.32

Dividend/share

N/A

EPS

$0.6

Enterprise value

$1.77B

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
Catalyst Pharmaceuticals's quick ratio has surged by 86% QoQ and by 46% YoY
Catalyst Pharmaceuticals's equity has surged by 68% YoY and by 45% QoQ
The stock's P/E is 70% more than its 5-year quarterly average of 17.0 and 39% more than its last 4 quarters average of 20.9
The EPS has declined by 37% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.catalystpharma.com
Peers: SRPT JNJ BMRN ABT

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
118.12M
Market cap
$2.08B
Enterprise value
$1.77B
Valuations
Price to earnings (P/E)
29.32
Price to book (P/B)
3.69
Price to sales (P/S)
4.99
EV/EBIT
20.52
EV/EBITDA
14.48
EV/Sales
4.3
Earnings
Revenue
$411.35M
EBIT
$86.29M
EBITDA
$122.26M
Free cash flow
$163.1M
Per share
EPS
$0.6
Free cash flow per share
$1.4
Book value per share
$4.76
Revenue per share
$3.52
TBVPS
$3.96
Balance sheet
Total assets
$646.68M
Total liabilities
$85.26M
Debt
$3.09M
Equity
$561.41M
Working capital
$325.04M
Liquidity
Debt to equity
0.01
Current ratio
5.09
Quick ratio
4.66
Net debt/EBITDA
-2.51
Margins
EBITDA margin
29.7%
Gross margin
86.7%
Net margin
15.8%
Operating margin
19%
Efficiency
Return on assets
13.2%
Return on equity
15.6%
Return on invested capital
137.2%
Return on capital employed
15.2%
Return on sales
21%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
1.27%
1 week
3.84%
1 month
16.64%
1 year
32.16%
YTD
4.64%
QTD
13.56%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$411.35M
Gross profit
$356.81M
Operating income
$78.33M
Net income
$65.12M
Gross margin
86.7%
Net margin
15.8%
Catalyst Pharmaceuticals's gross profit has surged by 64% YoY and by 3.1% QoQ
The revenue has soared by 60% YoY and by 3.3% QoQ
The operating margin has shrunk by 59% YoY and by 13% QoQ
Catalyst Pharmaceuticals's net margin has shrunk by 59% YoY and by 12% QoQ

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
CPRX P/E details
P/E
29.32
P/B
3.69
P/S
4.99
EV/EBIT
20.52
EV/EBITDA
14.48
EV/Sales
4.3
The stock's P/E is 70% more than its 5-year quarterly average of 17.0 and 39% more than its last 4 quarters average of 20.9
The EPS has declined by 37% year-on-year and by 10% since the previous quarter
Catalyst Pharmaceuticals's equity has surged by 68% YoY and by 45% QoQ
The stock's price to book (P/B) is 6% less than its 5-year quarterly average of 3.9 and 3.9% less than its last 4 quarters average of 3.8
The revenue has soared by 60% YoY and by 3.3% QoQ
The price to sales (P/S) is 15% higher than the last 4 quarters average of 4.3 and 2.7% higher than the 5-year quarterly average of 4.8

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has dropped by 85% year-on-year and by 28% since the previous quarter
The ROS has dropped by 57% year-on-year and by 11% since the previous quarter
The ROE has plunged by 55% YoY and by 21% from the previous quarter
CPRX's return on assets has dropped by 54% year-on-year and by 20% since the previous quarter

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
Catalyst Pharmaceuticals's quick ratio has surged by 86% QoQ and by 46% YoY
CPRX's current ratio has soared by 77% since the previous quarter and by 45% year-on-year
Catalyst Pharmaceuticals's debt is 99% lower than its equity
Catalyst Pharmaceuticals's equity has surged by 68% YoY and by 45% QoQ
Catalyst Pharmaceuticals's debt has decreased by 11% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.